ELICIO THERAPEUTICS INC (ELTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ELTX • US28657F1030

8.32 USD
+0.71 (+9.33%)
Last: Feb 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

ELTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. ELTX has a bad profitability rating. Also its financial health evaluation is rather negative. ELTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ELTX has reported negative net income.
  • ELTX had a negative operating cash flow in the past year.
  • In the past 5 years ELTX always reported negative net income.
  • ELTX had a negative operating cash flow in each of the past 5 years.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -162.13%, ELTX is doing worse than 85.71% of the companies in the same industry.
  • With a Return On Equity value of -1201.70%, ELTX is not doing good in the industry: 79.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -162.13%
ROE -1201.7%
ROIC N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ELTX has been increased compared to 1 year ago.
  • Compared to 5 years ago, ELTX has more shares outstanding
  • Compared to 1 year ago, ELTX has a worse debt to assets ratio.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ELTX has an Altman-Z score of -11.92. This is a bad value and indicates that ELTX is not financially healthy and even has some risk of bankruptcy.
  • ELTX has a Altman-Z score of -11.92. This is in the lower half of the industry: ELTX underperforms 75.05% of its industry peers.
  • ELTX has a Debt/Equity ratio of 2.55. This is a high value indicating a heavy dependency on external financing.
  • ELTX has a worse Debt to Equity ratio (2.55) than 78.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.55
Debt/FCF N/A
Altman-Z -11.92
ROIC/WACCN/A
WACCN/A
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • ELTX has a Current Ratio of 3.29. This indicates that ELTX is financially healthy and has no problem in meeting its short term obligations.
  • ELTX has a worse Current ratio (3.29) than 60.38% of its industry peers.
  • ELTX has a Quick Ratio of 3.29. This indicates that ELTX is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.29, ELTX perfoms like the industry average, outperforming 42.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ELTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.11%, which is quite impressive.
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.30% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.16%
EPS Next 2Y27.85%
EPS Next 3Y18.4%
EPS Next 5Y13.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • ELTX's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.85%
EPS Next 3Y18.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ELTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (2/6/2026, 8:00:01 PM)

8.32

+0.71 (+9.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners11.81%
Inst Owner Change4.03%
Ins Owners1.51%
Ins Owner Change35.77%
Market Cap145.52M
Revenue(TTM)N/A
Net Income(TTM)-45.86M
Analysts82.5
Price Target15.81 (90.02%)
Short Float %10.48%
Short Ratio11.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.71%
Min EPS beat(2)-6.95%
Max EPS beat(2)5.54%
EPS beat(4)1
Avg EPS beat(4)-4.62%
Min EPS beat(4)-14.29%
Max EPS beat(4)5.54%
EPS beat(8)2
Avg EPS beat(8)-24.06%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.3%
EPS NY rev (1m)0%
EPS NY rev (3m)6.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 38.13
P/tB 38.13
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-2.23
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -162.13%
ROE -1201.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -11.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -11.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.79%
Cap/Depr(5y)101.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.83%
EPS Next Y39.16%
EPS Next 2Y27.85%
EPS Next 3Y18.4%
EPS Next 5Y13.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.85%
OCF growth 3YN/A
OCF growth 5YN/A

ELICIO THERAPEUTICS INC / ELTX FAQ

Can you provide the ChartMill fundamental rating for ELICIO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELTX.


Can you provide the valuation status for ELICIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ELICIO THERAPEUTICS INC (ELTX). This can be considered as Overvalued.


Can you provide the profitability details for ELICIO THERAPEUTICS INC?

ELICIO THERAPEUTICS INC (ELTX) has a profitability rating of 0 / 10.